+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
PFIZER
₹3,910.00 +54 (1.4%)
26.77% Fall from 52W High

08 Nov, 2026 3:29 PM (IST)

Pfizer live price: ₹3,910.00. It opened at ₹3,868 vs previous close ₹3,856; intraday high/low: ₹3,924/₹3,866. The 50 & 200 DMA stand at ₹4,007.00/₹4,476.50.

Pfizer Performance

  • Today's Low
  • ₹3,866
  • Today's High
  • ₹3,924
  • 52 Week Low
  • ₹3,589
  • 52 Week High
  • ₹5,339
  • Open Price₹3,868
  • Previous Close₹3,856
  • Volume11,118
  • 50 DMA₹4,007.00
  • 100 DMA₹4,239.10
  • 200 DMA₹4,476.50

Pfizer Chart

Investment Returns

  • Over 1 Month + 2.49%
  • Over 3 Month -19.89%
  • Over 6 Month -17.69%
  • Over 1 Year -22.96%

Smart Investing Starts Here Start SIP with Pfizer for Steady Growth!

Invest Now

Pfizer Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 20.8
  • PEG Ratio
  • 8.7
  • Market Cap Cr
  • 17,887
  • P/B Ratio
  • 4.1
  • Average True Range
  • 107.5
  • EPS
  • 187.9
  • Dividend Yield
  • 1.9
  • MACD Signal
  • -44.8
  • RSI
  • 53.5
  • MFI
  • 74.18

Latest Stock News Updates

Pfizer Q2 results: Net profit rises 65.7% to 313 cr, income at 774 cr

Drugmaker Pfizer Ltd on Tuesday reported a 65.72 per cent increase in net profit to Rs 313.25 crore in the September quarter, driven by gains from exceptional items. The company had posted a profit of Rs 189 crore in the corresponding period of the previous fiscal year, Pfizer said in a regulatory filing. Pfizer has accounted for exceptional gains of Rs 132.06 crore in the September quarter from its parent entity Pfizer Inc USA following the sale of Minipress XL. Consequent to the decision, Pfizer Ltd discontinued the manufacture of Minipress XL from September 7, 2026, according to the filing. Its profit before tax and exceptional items stood at Rs 290.77 crore during the quarter under review, up 13.86 per cent year-on-year. It was at Rs 255.37 crore in the corresponding quarter of the previous fiscal year. Its total income rose to Rs 774.19 crore during the quarter under review from Rs 684.19 crore in the year-ago period. Pfizer reported an increase in total expenses to Rs 483.2

Q2FY27 Quarterly Result Announced for Pfizer Ltd.

<h3><span style="font-size:16px;"><strong>Pharmaceuticals company Pfizer announced Q2FY27 results</strong></span></h3> <p><strong data-complete="true" data-processed="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="f0jye_1r">Financial Highlights:<!--TgQPHd|||[]--></strong><!--TgQPHd|||[]--><br /> <!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></p> <ul data-complete="true" data-hveid="CAAIChAA" data-processed="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="wiLEJc#NS0kde" jsuid="f0jye_1x"> <li data-complete="true" data-hveid="CAAIChAF" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="f0jye_29"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="f0jye_2b">Total income:<!--TgQPHd|||[]--></strong> For Q2FY27, Total income was Rs 774.19 crore, growing by 10.91% QoQ from Rs 698.01 crore in Q1FY27 and by 13.15% YoY from Rs 684.19 crore in Q2FY26. For H1FY27, Total income achieved Rs 1,472.20 crore, registering an 8.70% YoY increase from Rs 1,354.41 crore in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAIChAI" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="f0jye_2i"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="f0jye_2k">Revenue from operations:<!--TgQPHd|||[]--></strong> During Q2FY27, Revenue from operations stood at Rs 726.86 crore, shifting upwards by 11.28% QoQ from Rs 653.17 crore in Q1FY27 and up 13.16% YoY from Rs 642.34 crore in Q2FY26. For H1FY27, cumulative Revenue from operations was Rs 1,380.03 crore, marking a 10.81% YoY increase from Rs 1,245.39 crore in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAIChAL" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="f0jye_2r"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="f0jye_2t">Profit Before Tax (PBT):<!--TgQPHd|||[]--></strong> For Q2FY27, PBT reached Rs 422.83 crore, showing a sequential increase of 52.82% QoQ against Rs 276.68 crore in Q1FY27 and an annual increase of 65.58% YoY against Rs 255.37 crore in Q2FY26. For H1FY27, PBT stood at Rs 699.51 crore, rising 35.85% YoY from Rs 514.90 crore in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAIChAO" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="f0jye_30"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="f0jye_32">Profit After Tax (PAT):<!--TgQPHd|||[]--></strong> Standalone PAT for Q2FY27 was reported at Rs 313.25 crore, increasing by 53.20% QoQ from Rs 204.47 crore in Q1FY27 and expanding by 65.72% YoY from Rs 189.02 crore in Q2FY26. For H1FY27, PAT reached Rs 517.72 crore, representing a 35.97% YoY growth over Rs 380.77 crore in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAIChAR" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="f0jye_39"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="f0jye_3b">Earnings Per Share (EPS):<!--TgQPHd|||[]--></strong> Basic and Diluted EPS for Q2FY27 was Rs 68.47, demonstrating a 53.21% QoQ change from Rs 44.69 in Q1FY27 and a 65.71% YoY change from Rs 41.32 in Q2FY26. For H1FY27, EPS stood at Rs 113.17, highlighting a 35.97% YoY improvement over Rs 83.23 in H1FY26.</li> </ul> <p><a class="lb" href="/get-document/post/pdf/5925914/" target="_blank">Result PDF</a></p>

Pfizer Ltd - 500680 - Board Meeting Outcome for Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2026.

Please find enclosed unaudited financial results for the quarter and half year ended September 30, 2026 along with the limited review report.

Pfizer Financials

Pfizer Technicals

EMA & SMA

Current Price
₹3,910.00
+ 54 (1.4%)
pointer
  • Bearish Moving Average 7
  • Bullish Moving Average 9
  • 20 Day
  • ₹3,820.20
  • 50 Day
  • ₹4,007.00
  • 100 Day
  • ₹4,239.10
  • 200 Day
  • ₹4,476.50

Resistance and Support

3899.87 Pivot Speed
  • R3 3,988.40
  • R2 3,956.20
  • R1 3,930.00
  • S1 3,871.60
  • S2 3,839.40
  • S3 3,813.20

Pfizer Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-11-03 Quarterly Results
2026-07-28 Quarterly Results
2026-05-12 Audited Results & Final Dividend
2026-02-09 Quarterly Results
2025-11-12 Quarterly Results
Date Purpose Remarks
2026-07-17 FINAL Rs.75.00 per share(750%)Final Dividend
2025-07-09 SPECIAL Rs.130.00 per share(1300%)Special Dividend
2025-07-09 FINAL Rs.35.00 per share(350%)Final Dividend
2024-08-21 FINAL Rs.35.00 per share(350%)Final Dividend
2023-08-11 SPECIAL Rs.5.00 per share(50%)Special Dividend
View Pfizer Dividend History Arrow

Pfizer Shareholding Pattern

63.92%
16.93%
12.83%
4.69%
1.63%

About Pfizer

Pfizer is engaged in manufacturing, marketing, distribution and trading of pharmaceutical products. The Company has its own manufacturing facility at Goa. The Company has various independent contract / third party manufacturers based across the country. The Company sells its products primarily in India through independent distributors. View More
  • NSE Symbol
  • PFIZER
  • BSE Symbol
  • 500680
  • Executive Director,Managing Director,Chief Executive Officer
  • Meenakshi Nevatia
  • ISIN
  • INE182A01018

Similar Stocks to Pfizer

Pfizer FAQs

Pfizer share price is ₹3,910 As on 09 November, 2026 | 05:20

The Market Cap of Pfizer is ₹17887.4 Cr As on 09 November, 2026 | 05:20

The P/E ratio of Pfizer is 20.8 As on 09 November, 2026 | 05:20

The PB ratio of Pfizer is 4.1 As on 09 November, 2026 | 05:20

The 52 week High & Low of Pfizer is ₹5339/₹3589 respectively As on 09 November, 2026 | 05:20

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23